NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Read More
Tag: CDK4/6 inhibito
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
